STAT Health has unveiled a groundbreaking 24/7 in-ear wearable designed to measure blood flow to the head, providing insights into symptoms like dizziness, brain fog, headaches, fainting, and fatigue upon standing. These symptoms are prevalent in conditions such as long COVID, postural orthostatic tachycardia syndrome (POTS), and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), affecting over 13 million Americans. Developed in collaboration with Johns Hopkins, Brigham and Women’s, and Harvard Medical School, the device employs an optical sensor, replacing traditional ultrasound, to gauge Cerebral Blood Flow (CBF) as a key biomarker. Clinical testing at Johns Hopkins and peer-reviewed in the Journal of the American College of Cardiology demonstrated the device’s ability to predict fainting minutes before its occurrence, offering a crucial objective measure for «invisible illnesses.» The device addresses the challenge of accurately measuring CBF, which is often approximated using secondary metrics like Heart Rate and Blood Pressure, leading to misdiagnoses of psychological causes for physiological abnormalities.

Article written by Syed Hamza Sohail| Image by Unsplash



HIT consultant